Sprint Bioscience AB publ announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced total revenue was SEK 1.492 million compared to SEK 5.414 million a year ago. Operating loss was SEK 13.045 million compared to SEK 10.222 million a year ago. Net loss was SEK 14.524 million compared to SEK 11.020 million a year ago.